Rating Change
BMO Capital reiterated its Outperform rating on Merck & Co., Inc. (NYSE:MRK) on August 20, 2026.
reiterateNYSE:MRK
BMO Capital Reiterates Outperform Rating on Merck & Co., Inc. (MRK)
BMO Capital reiterated its Outperform rating on Merck & Co., Inc. (NYSE:MRK) on August 20, 2026.
At publication ·
What changed
Merck & Co., Inc. (NYSE:MRK) · reiterate
- Firm
- BMO Capital
- Rating
- Outperform to Outperform
- Price at event
- $149.25
- Market capitalization
- $248.8B
At a glance
Key takeaways
- BMO Capital reiterated an Outperform rating on Merck & Co. (MRK) on August 20, 2026, with the stock trading at $149.25 and a market capitalization of $248.8 billion.
Market Context
Merck & Co., Inc. operates in the Healthcare sector. The stock currently trades at $149.25 with a market capitalization of $248.8B. The stock has gained 45.2% over the past 52 weeks.
Analyst coverage from BMO Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Merck & Co., Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Merck & Co., Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 20, 2026 | UBS | Buy | N/A |
| Aug 20, 2026 | BMO Capital | Outperform | N/A |
| Aug 20, 2026 | RBC Capital | Sector Perform | N/A |
| Aug 20, 2026 | Morgan Stanley | Overweight | N/A |
| Aug 12, 2026 | Daiwa Capital | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View MRK Stock Page
Frequently Asked Questions
What does the Outperform rating mean for MRK?
A rating of Outperform from BMO Capital reflects the analyst's outlook on Merck & Co., Inc. (NYSE:MRK). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MRK forecast page.
